e-Therapeutics outlines goals for 2012 and anno...

e-Therapeutics outlines goals for 2012 and announces presentation at Biotech Showcase Conference

e-Therapeutics plc

e-Therapeutics outlines goals for 2012 and announces presentation at Biotech Showcase Conference

Oxford and Newcastle, UK, 9 January 2012 - Drug discovery and development company e-Therapeutics plc (AIM: ETX) today provides an update on its goals and expectations for 2012.

• Four drugs to enter clinical trials
  • ETS2101 (anti-cancer drug; phase I programme starting in Q1)
  • ETX1153c (phase I trial for C. difficile infection starting in Q2)
  • ETS6103 (anti-depressant; phase IIb trial starting in Q3*)
  • ETX1153a (phase I trial in MRSA starting in Q4)
• First data expected from clinical trials programme
  • ETS2101 – initial findings from phase I programme in Q4
  • ETX1153c – phase I data in Q4

e-Therapeutics’ CEO, Professor Malcolm Young, said: “This is an important year for e-Therapeutics, as we advance multiple drugs into the clinic and look forward to the first data from our programme of trials. We remain equally focused on drug discovery, where our strengthened team is on track to deliver new candidates for development next year.”

An overview of the Company’s strategy, drug discovery platform and clinical development programmes will be presented by Professor Young at the Biotech Showcase Conference at the Parc 55 Wyndham Hotel in San Francisco on Wednesday 11 January at 10.30 am PST (18:30 BST).

A webcast of the presentation will be available on e-Therapeutics’ website at http://www.etherapeutics.co.uk

For live viewing of the webcast, it is recommended that viewers log on 15 minutes early in order to register and download any necessary software.

*Data now expected in H2 2013.

About e-Therapeutics

e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on the science of complex systems. The Company’s discovery activity is focused in cancer and degenerative diseases of the nervous system and its development effort on four clinical candidates spanning cancer, psychiatric disorders and infectious diseases. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.

Contacts:

e-Therapeutics plc

Malcolm Young / Daniel Elger

Tel: [phone]

www.etherapeutics.co.uk

Panmure Gordon (UK) Limited

Andrew Burnett / Fred Walsh

Tel: [phone]

www.panmure.com

College Hill

Melanie Toyne Sewell/Jayne Crook

Tel: [phone]

Email: [e-mail]

CommStrat Group (US)

Ted Agne

Tel: [phone]

Email: [e-mail]